About Constellation Pharma
Constellation Pharma is a company based in Cambridge (United States) founded in 2008 was acquired by MorphoSys in June 2021. Constellation Pharma has raised $349.37 million across 9 funding rounds from investors including Fidelity Investments, MorphoSys and Genentech. The company has 142 employees as of December 31, 2021. Constellation Pharma operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Employees 142 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$349.37 M (USD)
in 9 rounds
-
Latest Funding Round
$65 M (USD), Post-IPO
Oct 01, 2019
-
Investors
Fidelity Investments
& 18 more
-
Employee Count
142
as on Dec 31, 2021
-
Acquired by
MorphoSys
(Jun 02, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Constellation Pharma
Unlock access to complete
Funding Insights of Constellation Pharma
Constellation Pharma has successfully raised a total of $349.37M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Constellation Pharma
Constellation Pharma has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, MorphoSys and Genentech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC & PE firm focused on healthcare sector
|
Locked | Locked | Locked | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked |
Investor details for Constellation Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Constellation Pharma
Investment portfolio details for Constellation Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Constellation Pharma
Detailed financials for Constellation Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Constellation Pharma Comparisons
Peer comparison for Constellation Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Constellation Pharma
Constellation Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Constellation Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Constellation Pharma
Complete news archive for Constellation Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Constellation Pharma
Constellation Pharma was founded in 2008.
Constellation Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Constellation Pharma is a funded company, having raised a total of $349.37M across 9 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Constellation Pharma is 142.
Constellation Pharma was founded in 2008 and is based in Cambridge, United States. Operations are centered in the biotechnology sector, where drugs are developed in the field of epigenetics. The pipeline features inhibitors of bromodomain and extra-terminal proteins, which regulate gene expression, along with small molecules targeting EZH2, a histone methyltransferase in the PRC2 complex. Focus is placed on advancing these therapies through research and development.
Constellation Pharma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Constellation Pharma has 19 investors. Key investors include Fidelity Investments, MorphoSys, Genentech, Orbimed, and The Column Group.